GeNeuro Announces Approval of all Resolutions Proposed at 12 June 2024 Annual General Meeting
GeNeuro Announces Approval of all ResolutionsProposed at 2024 Annual General Meeting Geneva, Switzerland, June 14, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), […]